Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma
Memorial Sloan Kettering Cancer Center
Summary
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patient, or legally authorized representative (LAR), willing and able to provide written informed consent for the trial * Patient age ≥ 18 at time of consent * Pathologically confirmed diffuse pleural mesothelioma * Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof) * Measurable disease as defined primarily by the modified RECIST criteria for mesothelioma (at PI discretion RECIST v1.1 may be used) * Consent to undergo a biopsy prior to Cycle 1 Day 1 and Cycle 3 Day 1 if deemed medically safe and feasible *…
Interventions
- DrugSacituzumab govitecan-hziy
After enrollment, participants will receive SG until disease progression or intolerable toxicity.
Locations (7)
- Memorial Sloan Kettering Basking RidgeBasking Ridge, New Jersey
- Memorial Sloan Kettering MonmouthMiddletown, New Jersey
- Memorial Sloan Kettering BergenMontvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ CommackCommack, New York
- Memorial Sloan Kettering WestchesterHarrison, New York
- Memorial Sloan - Kettering Cancer CenterNew York, New York